Skip to main content
. 2021 Apr;9(7):569. doi: 10.21037/atm-21-463

Figure 6.

Figure 6

Immune signature predicted the immunotherapeutic benefits in lung squamous cell carcinoma. (A,B,C,D) mRNA expression of PDCD1, CD274, CTLA-4, and MLH1 in the low-risk and high-risk groups. (E) Distribution of tumor-infiltrating lymphocytes. (F) Distribution of cytotoxic activity scores. (G) Distribution of T-cell-inflamed GEP. (H) Distribution of TIDE score. GEP, gene expression profile; TIDE, tumor immune dysfunction and exclusion.